Trial Profile

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; K NK002 (Primary) ; Fludarabine; Melphalan
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus First in man; Proof of concept; Therapeutic Use
Acronyms NK-REALM
Sponsors CytoSen Therapeutics; Kiadis Pharma

Most Recent Events

16 Jun 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
23 Feb 2021 Planned End Date changed from 1 Mar 2023 to 1 Nov 2023.
23 Feb 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com